Rituximab induces complete remission in a case of membranous nephropathy associated with hepatitis C virus-related infection [9]

Nephrology Dialysis Transplantation

Volumn 22, Issue 12, 2007, Pages 3674-3676

  Pansini, Francesca ^a   Bonifati, Carmen ^a   Manno, Carlo ^a   Schena, Francesco Paolo ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ENALAPRIL; IMMUNOGLOBULIN G; PREDNISONE; RITUXIMAB;

AGED; CASE REPORT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOFLUORESCENCE; LETTER; LIVER BIOPSY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; NONHUMAN; PRIORITY JOURNAL; REMISSION;

AGED; ANTIBODIES, MONOCLONAL; GLOMERULONEPHRITIS, MEMBRANOUS; HEPATITIS C; HUMANS; MALE; REMISSION INDUCTION;

EID: 36749081075     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm514     Document Type: Letter

References (4)

1. Hogan S, Muller KE, Jennette JC, Falk RG. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis 1995; 25: 862-875
2. Ruggenenti P, Chiurchiu C, Brusegan V et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 2003; 14: 1851-1857
3. Zaja F, De Vita S, Mazzaro C et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 10: 3827-3834
4. Marcus R, Hagenbeek A. The therapeutic use of rituximab in non-Hodgkin's lymphoma. Eur J Haematol Suppl 2007; 67: 5-14